Health-related quality-of-life outcomes from a phase II open-label trial of two different starting doses of lenvatinib in combination with everolimus for treatment of renal cell carcinoma following one prior VEGF-targeted treatment.

Cristiane Decat Bergerot(MedSIR (Spain)), Javier Puente(Hospital Clínico San Carlos), B. Yа. Alekseev(P.A. Hertzen Moscow Oncology Research Institute), Daniel Castellano(Universidad Complutense de Madrid), Sun Young Rha(Yonsei University), Karen O’Hara(Eisai (United States)), Sumanta K. Pal(City of Hope), Kaisa Sunela(Tampere University Hospital), L. Michelle Bennett(RTI Health Solutions), Jae‐Lyun Lee(Ulsan College), Daniil Stroyakovskiy(Shikoku Cancer Center), P. Koralewski(Unknown), Jinyi Wang(RTI Health Solutions), Francis Parnis(Centre for Cancer Biology), Janice Pan(Eisai (United States)), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), Daniel Yick Chin Heng(University of Calgary), Hilary Glen(Beatson West of Scotland Cancer Centre)
Journal of Clinical Oncology
February 20, 2021
10.1200/jco.2021.39.6_suppl.314
Cited by 1

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
|The Lancet|2005|2.1k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k